<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077332</url>
  </required_header>
  <id_info>
    <org_study_id>LDOS-21-001</org_study_id>
    <nct_id>NCT05077332</nct_id>
  </id_info>
  <brief_title>LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)</brief_title>
  <official_title>Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leidos Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Leidos Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This master protocol serves as a common reference for the inpatient and outpatient clinical&#xD;
      studies that share common elements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are currently two addenda to this master protocol:&#xD;
&#xD;
      Addendum 1, Study LDOS-21-001-01, is a Phase 2, randomized, double-blind, placebo-controlled&#xD;
      study to evaluate the safety and efficacy of the combination of famotidine and celecoxib as a&#xD;
      treatment in moderate-to-severe patients hospitalized for COVID-19.&#xD;
&#xD;
      Addendum 2, Study LDOS-21-001-02, is a Phase 2 randomized, placebo-controlled, double-blind&#xD;
      study to evaluate the safety and efficacy of the combination of famotidine and celecoxib as a&#xD;
      post-exposure prophylaxis (PEP) for newly infected COVID-19 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects randomized 1:1, study drug:placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(LDOS-21-001-01) Time-to-event to achieve WHO level ≤3</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluation of the time-to-event to achieve a WHO level score ≤3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(LDOS-21-001-01) Death rate</measure>
    <time_frame>30 days</time_frame>
    <description>Measured in whole numbers by participants removed from the study with reason of &quot;death&quot; in the electronic data capture system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to increased COVID-19 symptom severity</measure>
    <time_frame>30 days</time_frame>
    <description>Medically attended contact will be measured in whole numbers and reported as &quot;1 medically attended contact&quot; each time, in the electronic data capture system for all study participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(LDOS-21-001-02) Number of patients with at least one COVID-19-related medically attended contact due to death (all-cause mortality)</measure>
    <time_frame>30 days</time_frame>
    <description>Medically attended contact will be measured in whole numbers and reported as &quot;1 medically attended contact&quot; in the electronic data capture system for all study participants.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>2019 Novel Coronavirus Disease</condition>
  <condition>2019 Novel Coronavirus Infection</condition>
  <condition>2019-nCoV Disease</condition>
  <condition>2019-nCoV Infection</condition>
  <condition>COVID-19 Pandemic</condition>
  <condition>COVID-19 Virus Disease</condition>
  <condition>COVID-19 Virus Infection</condition>
  <condition>Covid19</condition>
  <condition>Coronavirus Disease 2019</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, participants will continue their famotidine treatment for an additional 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>80 mg tablet, QID for 14 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Pepcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg (initial dose) then 200 mg capsule, BID for 5 days</description>
    <arm_group_label>Group 1 (Study Product)</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet, QID for 14 days; capsule, BID for 5 days</description>
    <arm_group_label>Group 2 (Reference Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  For eligibility criteria specific to the protocol, see:&#xD;
&#xD;
          -  Addendum #1 (LDOS-21-001-01) or&#xD;
&#xD;
          -  Addendum #2 (LDOS-21-001-02)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <role>Study Director</role>
    <affiliation>Leidos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian A Roberts, MS, PMP</last_name>
    <phone>240-529-0455</phone>
    <email>brian.a.roberts@leidos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tilly Lawrence, BSN, RN</last_name>
    <phone>240-529-0497</phone>
    <email>tilly.lawrence@leidos.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol. 2021 Mar 23;12:633680. doi: 10.3389/fphar.2021.633680. eCollection 2021.</citation>
    <PMID>33833683</PMID>
  </reference>
  <reference>
    <citation>Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.</citation>
    <PMID>32499303</PMID>
  </reference>
  <reference>
    <citation>Hogan Ii RB, Hogan Iii RB, Cannon T, Rappai M, Studdard J, Paul D, Dooley TP. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020 Aug;63:101942. doi: 10.1016/j.pupt.2020.101942. Epub 2020 Aug 29.</citation>
    <PMID>32871242</PMID>
  </reference>
  <reference>
    <citation>Tomera K, Malone R, Kittah J. Hospitalized COVID-19 Patients Treated with Celecoxib and High Dose Famotidine Adjuvant Therapy Sow Significant Clinical Responses. Frontiers in Pharmacology. 2021.</citation>
  </reference>
  <reference>
    <citation>Sun C, Chen Y, Hu L, Wu Y, Liang M, Ayaz Ahmed M, Bhan C, Guo Z, Yang H, Zuo Y, Yan Y, Zhou Q. Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis. Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.</citation>
    <PMID>33625613</PMID>
  </reference>
  <reference>
    <citation>Shoaibi A, Fortin SP, Weinstein R, Berlin JA, Ryan P. Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. Am J Gastroenterol. 2021 Apr;116(4):692-699. doi: 10.14309/ajg.0000000000001153.</citation>
    <PMID>33982938</PMID>
  </reference>
  <reference>
    <citation>Sander WJ, O'Neill HG, Pohl CH. Prostaglandin E(2) As a Modulator of Viral Infections. Front Physiol. 2017 Feb 14;8:89. doi: 10.3389/fphys.2017.00089. eCollection 2017. Review.</citation>
    <PMID>28261111</PMID>
  </reference>
  <reference>
    <citation>Morimoto K, Shirata N, Taketomi Y, Tsuchiya S, Segi-Nishida E, Inazumi T, Kabashima K, Tanaka S, Murakami M, Narumiya S, Sugimoto Y. Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation. J Immunol. 2014 Feb 1;192(3):1130-7. doi: 10.4049/jimmunol.1300290. Epub 2013 Dec 16.</citation>
    <PMID>24342806</PMID>
  </reference>
  <reference>
    <citation>Hong W, Chen Y, You K, Tan S, Wu F, Tao J, Chen X, Zhang J, Xiong Y, Yuan F, Yang Z, Chen T, Chen X, Peng P, Tai Q, Wang J, Zhang F, Li YX. Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study. Front Pharmacol. 2020 Nov 6;11:561674. doi: 10.3389/fphar.2020.561674. eCollection 2020.</citation>
    <PMID>33312125</PMID>
  </reference>
  <reference>
    <citation>Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, Wilen CB. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J Virol. 2021 Jan 13. pii: JVI.00014-21. doi: 10.1128/JVI.00014-21. [Epub ahead of print]</citation>
    <PMID>33441348</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID</keyword>
  <keyword>COVID19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

